
USPTO Focuses on Pharmaceutical Patent Quality in Proposed Initiatives
Continue reading
By Kelsey J. Roberts Kingman, Ph.D. - Edited by Teodora Groza
Posted on December 02, 2022
In July 2021, President Biden issued an Executive Order on promoting competition in the U.S. economy. Among other measures, the Executive Order called for action “to help ensure that the patent system, while incentivizing innovation, does not unjustifiably delay generic drug or biosimilar competition beyond that reasonably contemplated by applicable law." Against this backdrop, the U.S. Patent and Trademark Office...
Continue reading